Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Offers Two Paths To “Coverage With Evidence” In Revised Guidance

This article was originally published in The Gray Sheet

Executive Summary

CMS introduces two distinct categories of coverage-with-evidence-development determinations in long-awaited 1guidelines issued July 12

Related Content

What Ails Coverage With Evidence Development? MedPAC Discusses Issues
CMS Sticks To Status Quo On Clinical Research Coverage, For Now
Evidence Development Gets Title Role In CMS Coverage Advisory Committee
Advisory Committee To Discuss Changes To CMS’ Trial Payment Policy
Increased Patient Registry Use Has Industry Looking For Direction
McClellan’s Farewell Gifts Include Direction For Technology Council
Wingspan Coverage Policy Has Broad Implications For Humanitarian Devices
Bioethicists Advocate Cost Criterion For Coverage With Evidence Development
CMS Suggests Noncoverage of Boston Sci Wingspan, Except In Clinical Trials
Trade Groups Vet CMS’ Coverage-With-Evidence Development Guidance



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts